Top Page
Jacobson Pharma Corporation Limited
(2633)
Jacobson Pharma Corporation Limited (2633) vs. iShares MSCI Hong Kong ETF (EWH)
Jacobson Pharma Corporation Limited Business Overview & Revenue Model
Jacobson Pharma Corporation Limited Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.58B | 1.47B | 1.79B | 1.60B | 1.45B |
| Gross Profit | 692.94M | 620.48M | 747.17M | 620.52M | 534.15M |
| EBITDA | 558.87M | 489.81M | 462.04M | 415.49M | 377.20M |
| Net Income | 300.83M | 266.97M | 251.04M | 177.67M | 173.71M |
Balance Sheet | |||||
| Total Assets | 3.65B | 3.49B | 5.38B | 4.76B | 4.87B |
| Cash, Cash Equivalents and Short-Term Investments | 509.05M | 411.94M | 1.04B | 478.65M | 480.35M |
| Total Debt | 773.21M | 749.38M | 1.60B | 1.41B | 1.65B |
| Total Liabilities | 1.17B | 1.09B | 2.12B | 1.80B | 2.01B |
| Stockholders Equity | 2.45B | 2.37B | 2.74B | 2.49B | 2.39B |
Cash Flow | |||||
| Free Cash Flow | 278.39M | 354.85M | 585.23M | 345.89M | 347.99M |
| Operating Cash Flow | 526.78M | 484.36M | 648.24M | 409.76M | 411.35M |
| Investing Cash Flow | -297.76M | 43.34M | -44.09M | -52.75M | -375.40M |
| Financing Cash Flow | -131.30M | -1.05B | -45.64M | -357.89M | 21.36M |
Jacobson Pharma Corporation Limited Technical Analysis
Jacobson Pharma Corporation Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$6.43B | 7.06 | 11.61% | 6.05% | -18.09% | -15.08% | |
73 Outperform | HK$1.97B | 3.22 | 18.33% | 5.78% | -9.95% | 67.56% | |
72 Outperform | HK$2.40B | 12.13 | 19.22% | 6.86% | 20.65% | 63.21% | |
72 Outperform | HK$2.63B | 7.62 | 21.15% | 14.12% | 20.89% | 24.98% | |
67 Neutral | HK$2.81B | 9.77 | 12.47% | 4.03% | 7.43% | 21.88% | |
66 Neutral | HK$1.17B | 12.52 | 5.04% | 2.39% | 32.95% | 456.69% | |
54 Neutral | €4.17B | 12.59 | -36.14% | 2.46% | 15.95% | -24.06% |
Jacobson Pharma Corporation Limited Corporate Events
Jacobson Pharma Corporation Limited announced the results of its Annual General Meeting held on July 28, 2025, where all proposed resolutions were passed. Key outcomes include the approval of final and special dividends, re-election of directors, and the appointment of a new independent non-executive director. These decisions reflect the company’s strategic direction and commitment to shareholder value, potentially impacting its market position and stakeholder confidence.
Jacobson Pharma Corporation Limited announced the composition and roles of its board of directors and board committees, highlighting the leadership of Mr. Sum Kwong Yip, Derek as Chairman, CEO, and Executive Director. The announcement underscores the company’s governance structure, which includes committees focused on audit, remuneration, nomination, executive, and environmental, social, and governance matters, reflecting its commitment to comprehensive corporate governance.
Jacobson Pharma Corporation Limited has revised the terms of reference for its Nomination Committee, which plays a crucial role in identifying and evaluating candidates for the board of directors, as well as overseeing policies related to board and workforce diversity. The updated terms emphasize the importance of independent non-executive directors and gender diversity within the committee. This move is expected to enhance the governance and diversity of the company’s leadership, potentially improving its strategic decision-making and aligning with broader industry trends towards inclusivity.
Jacobson Pharma Corporation Limited has announced key dates for its upcoming Annual General Meeting and proposed dividends. The company has set the record date for shareholders to attend and vote at the meeting on July 28, 2025, with the register of members closed from July 22 to July 28, 2025. Additionally, the record date for entitlement to the proposed final and special dividends is set for August 14, 2025, with the register closed from August 13 to August 14, 2025. These announcements are crucial for shareholders as they outline the timeline for participation in corporate governance and potential financial benefits.
Jacobson Pharma Corporation Limited has announced its upcoming annual general meeting to be held virtually on July 28, 2025. Key agenda items include the approval of financial statements, declaration of final and special dividends, re-election of directors, and the reappointment of KPMG as auditor. Additionally, the company seeks shareholder approval for a mandate to repurchase up to 10% of its issued shares, which could impact the company’s stock liquidity and shareholder value.
Jacobson Pharma Corporation Limited announced its annual financial results for the year ending March 31, 2025, reporting a revenue increase of 7.4% to approximately HK$1,576.9 million. The company’s profit from operations rose by 24.5% to HK$414.6 million, and profit from continuing operations increased by 43.1% to HK$300.8 million. The Board has recommended a final cash dividend of HK5.50 cents per share and a special cash dividend of HK6.00 cents per share, reflecting a strong financial performance and commitment to returning value to shareholders.
Jacobson Pharma Corporation Limited has announced a final ordinary cash dividend of HKD 0.055 per share for the financial year ending March 31, 2025. This announcement reflects the company’s commitment to returning value to its shareholders and may enhance its attractiveness to investors, potentially impacting its market positioning positively.
Jacobson Pharma Corporation Limited has announced a special dividend of HKD 0.06 per share for the financial year ending 31 March 2025. This move reflects the company’s strong financial performance and commitment to delivering shareholder value. The dividend will be paid on 28 August 2025, with the ex-dividend date set for 11 August 2025, and the record date on 14 August 2025. This announcement is likely to positively impact the company’s market positioning and investor confidence.
Jacobson Pharma Corporation Limited announced the retirement of Professor Lam Sing Kwong, Simon from his role as an independent non-executive director, effective after the annual general meeting on July 28, 2025. Professor Lam, who has served since April 2016, will also step down from his positions on various committees, and the company is in the process of identifying a suitable replacement.
Jacobson Pharma Corporation Limited has announced a board meeting scheduled for June 13, 2025, to discuss and approve the company’s annual results for the fiscal year ending March 31, 2025. The meeting will also consider the recommendation of a final dividend and address any other business matters, potentially impacting the company’s financial strategy and stakeholder interests.
Jacobson Pharma Corporation Limited has announced a positive profit alert, expecting a more than 40% increase in profit from continuing operations for the fiscal year ending March 2025 compared to the previous year. This growth is attributed to strong performance in specialty medicines and generic drugs, new product launches, and effective cost control measures. Additionally, the profit attributable to equity shareholders is anticipated to rise by over 10%, following the distribution of JBM Healthcare shares as a special dividend.
Jacobson Pharma Corporation Limited announced its decision to increase its investment in Tycoon Group Holdings Limited by subscribing to additional shares. Despite a recent decline in Tycoon Group’s share prices, Jacobson Pharma views this as a strategic opportunity to enhance its long-term investment portfolio, given Tycoon Group’s resilient operational performance and favorable asset valuation. This move is expected to strengthen Jacobson Pharma’s position in the market and potentially offer significant returns to its stakeholders.